Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Innovation May Mean Collaborations for Drug Development in Future

Published: Wednesday, September 26, 2012
Last Updated: Wednesday, September 26, 2012
Bookmark and Share
Research collaborations and shared data will mark a change in the fiercely competitive pharmaceutical world, states a new report by healthcare experts GBI Research.

The new report states that academics, industry giants, regulators and patients’ organizations must work together in collaborative research projects in order for modern medicine to flourish.

Over the past decade, the number of New Drug Applications (NDAs) and Biologics License Applications (BLAs) approved by the US Food and Drug Administration (FDA) has fallen steadily, despite ever-increasing R&D expenditure. This gap between investment and success has led the pharmaceutical industry to rethink its business strategies, with industry professionals now working together in order to explore improved pathways for drug discovery and development.

Collaboration and open innovation through Public-Private Partnerships (PPPs) enables research that would not be possible for companies to undertake individually. The consortia tackle precompetitive research – fields of activity in which large companies agree to collaborate and invest in jointly, despite their rivalry in the drug market. Most companies agree that disease biology is a precompetitive science, but that once disease targets are identified, research becomes competitive. These projects aim to eliminate duplication of research, which would waste funding and resources, and also develop competition for samples and clinical trial participation within a single patient population.

The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a huge PPP, funded by the National Institutes of Health as well as private contributions from pharmaceutical partners through the Foundations for National Institutes of Health. Alzheimer’s disease is difficult to target, as it can progress for many years before symptoms become evident. The path of disease progression is unclear, and clinical trials for any new drug have to be very lengthy, and the failure of a drug to demonstrate efficacy represents both a huge loss of investments for pharma companies, and an ongoing lack of treatment options for patients.

The initiative has produced results which have fundamentally challenged the way in which clinical trials in Alzheimer’s disease should be conducted. Previously, the length of time over which the disease can progress without symptoms was not fully appreciated, and it has become clear that anti-amyloid treatments under investigation may prove far more effective in patients with the disease at an earlier stage than those currently included in clinical trials.

The ADNI represents one of the earliest large PPPs of its type, and stakeholders worked together to decide how to manage data and intellectual property. The decision to place all data into the public domain ensured there were no intellectual property issues, and opened the newly discovered research up to the world. Though is it still uncertain how commercial companies will deal with public access to their research, increased data leveraging undoubtedly makes more sense in the eyes of a scientist or patient.

The ADNI PPP has created a sense of shared responsibility in understanding Alzheimer’s disease and has improved the landscape for clinical research in the future. This could represent a major change to the way in which pharmaceuticals are researched and value created, setting the stage for future collaborations.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Self-Assembling, Biomimetic Membranes May Aid Water Filtration
A synthetic membrane that self assembles and is easily produced may lead to better gas separation, water purification, drug delivery and DNA recognition, according to an international team of researchers.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
Teeth Reveal Lifetime Exposures to Metals, Toxins
Researchers have identified dental biomarkers to reveal links between early iron exposure and late life brain diseases.
An Innovative Algorithm to Decipher How Drugs Work Inside the Body
Researchers at Columbia University Medical Center (CUMC) have developed a computer algorithm that is helping scientists see how drugs produce pharmacological effects inside the body.
Uncovering the Spread of Bacteria in Pneumonia
Northwestern Medicine scientists have discovered the role a toxin produced by a pneumonia-causing bacterium plays in the spread of infection from the lungs to the bloodstream in hospitalized patients.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!